Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 4;11:11836. doi: 10.1038/s41598-021-91382-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

RUNX1 and REXO2 hyper-methylation are associated with the favorable clinical outcomes of IDH wild type LGG or LGG or glioma patients. (a) Un-supervised clustering heatmaps demonstrated the differentially methylated genes between sub-cluster1 and sub-cluster2 IDH wild type LGG patients in TCGA dataset. Red represented the hyper-methylated genes and blue represented the hypo-methylated genes. (b) Box plots showed the methylation levels of RUNX1 and REXO2 in sub-cluster1 and sub-cluster2 IDH wild type LGG patients in TCGA dataset. (c) The Kaplan–Meier Plotters demonstrated the different clinical outcomes of IDH wild type LGG patients with RUNX1 hypo-methylation or with RUNX1 hyper-methylation in TCGA and CGGA datasets. (d) The Kaplan–Meier Plotters demonstrated the different clinical outcomes of IDH wild type LGG patients with REXO2 hypo-methylation or with REXO2 hyper-methylation in TCGA and CGGA datasets. (e) Box plots showed the methylation levels of RUNX1 and REXO2 in LGG patients with (red) or without (blue) IDH mutations in TCGA dataset. (f) The Kaplan–Meier Plotters showed the correlations of RUNX1, REXO2 methylation levels and LGG overall survival in TCGA dataset. (g) Box plots demonstrated the methylation levels of RUNX1 and REXO2 in grade II (LGG), grade III (LGG) or grade IV (GBM) glioma patients in TCGA dataset. (h) The Kaplan–Meier Plotters showed the correlations of RUNX1, REXO2 methylation levels and glioma overall survival in TCGA dataset.